Peanut oral immunotherapy – current trends in clinical trials

Simone Reinwald,1,2 Jennifer M. Rolland,1,2 Robyn E. O’Hehir,1,2 Menno C. van Zelm1,2

1 Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, VIC, Australia

2 Allergy, Asthma and Clinical Immunology Service, Respiratory Medicine, Central Clinical School, Monash University, and Alfred Hospital, Melbourne, VIC, Australia

Corresponding author: Menno C. van Zelm, PhD

Email: menno.vanzelm@monash.edu

Department of Immunology and Pathology
Central Clinical School, Monash University
89 Commercial Road, Melbourne VIC 3004, Australia

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Immunology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Immunotherapy for allergy has been practised for over 100 years. Low-dose repeated exposure to specific allergen extracts over several months to years can successfully induce clinical tolerance in patients with allergy to insect venoms, pollen, house dust mite and domestic animals. Different regimens and routes for immunotherapy include subcutaneous, sublingual, oral and intralymphatic. Food allergies have been difficult to treat in this way due to high anaphylactic potential and only recently the first immunotherapy for peanut allergy has received regulatory approval. Several clinical trials have indicated high efficacy in desensitisation of peanut-allergic individuals using oral immunotherapy, which allows for safer administration of relatively high allergen concentrations. Still, the risk of adverse events including serious allergic reactions and high anxiety levels for patients remains, demonstrating the need for further optimisation of treatment protocols. Here we discuss the design and outcomes of recent clinical trials with traditional oral immunotherapy, and consider alternative protocols and formulations for safer and more effective oral treatment strategies for peanut allergy.

Keywords: peanut allergy, oral immunotherapy, desensitisation, biological adjuvants, clinical trials
Abbreviations:

AD, atopic dermatitis; AIT, Allergen-specific immunotherapy; CTLA-4, cytotoxic T- Lymphocyte Antigen 4; DBPCFC, double-blind, placebo-controlled food challenge; DMARDs, disease modifying anti-rheumatic drugs; EPIT, epicutaneous immunotherapy; IFN, Interferon; IL, interleukin; LAMP, lysosomal associated membrane protein; mAb, monoclonal antibody; OEAOIT, Omalizumab-enabled accelerated oral immunotherapy; OIT, oral immunotherapy; PPOIT, probiotic with peanut OIT; REMS, risk evaluation and mitigation strategy; SCFA, short chain fatty acids; SLIT, sublingual immunotherapy; Th cell, T helper cell; Treg cell, T regulatory cell.
Introduction

Allergy to peanuts (Arachis hypogaea) is an IgE-mediated hypersensitivity, which tends to develop early in life and is typically lifelong with resolution in only 20% of affected children (1). Amongst all food allergies, peanut allergy accounts for the majority of severe allergic reactions worldwide (2). The four major peanut components of which the IgE reactivity is associated with clinically severe reactions are: Ara h 1 and Ara h 3, both members of the cupin superfamily; and Ara h 2 and Ara h 6, members of the prolamin superfamily of proteins (3). Of these four, Ara h 2 is the most specific marker allergen for severe reactions including anaphylaxis (4). In total, 16 peanut proteins are registered as allergens to date (5). Some of these have been characterised fully, others only partially and there may be additional, as yet unidentified protein allergens. Importantly, reactivity to some peanut components (especially Ara h 8 and 9) result from cross-reactivity to allergens in other plants and is associated with mild responses or even tolerance (6).

Allergen-specific immunotherapy (AIT) aims to increase the threshold for reactivity towards a specific allergen. The advantage of AIT is that it only modifies the immune response to the allergen of concern while not affecting the immune system at large. AIT is typically provided via regular administration of gradually increasing allergen doses. The underlying immunological mechanisms occurring over the course of AIT are subjects of current research. In general, there is a skewing of the immune response to that particular antigen away from the pro-allergenic Th2 cell activity towards an increase in Th1 cells and Interleukin (IL)-10 production by regulatory T (Treg) cells. These changes modify the B cell response and cause a change in the IgE/IgG4 ratio (7, 8). Allergen-specific IgG4 antibodies may inhibit IgE-mediated degranulation of target cells, which is one underlying observation in clinical tolerance (7).

Clinical trials over the last decade have evaluated various protocols of immunotherapy for peanut allergy, which typically involve the administration of gradually increasing amounts of peanut
protein up to a defined maintenance dose via either the gastrointestinal tract, categorised as oral immunotherapy (OIT) or sublingual immunotherapy (SLIT), or via the skin, categorised as epicutaneous immunotherapy (EPIT) (9). Epicutaneous and sublingual delivery of allergens shows very good tolerability but lower efficacy compared to OIT protocols (10). Viaskin-mediated EPIT (DBV Technologies, France and US) represents an innovative epidermal powder delivery system in a patch containing 250 μg peanut protein, and has been shown to successfully increase peanut tolerance in clinical studies without evoking anaphylaxis (Table 1) (11). Although this delivery system has a better safety record, its efficacy is modest with demonstrated benefit only in a subgroup of patients up to the age of 11 years (12).

For SLIT, peanut allergen is dissolved under the tongue for 2 min where it is taken up by oral Langerhans cells and subsequently presented to immune cells in the draining lymph nodes. The peanut SLIT extract is then swallowed, but the dose is 100–1000 times smaller than those used in peanut OIT. Results from a long-term trial in children aged 1 to 11 years old showed partial but clinically significant desensitisation with only rare withdrawals from adverse events and no epinephrine usage (Table 1) (13).

Among the immunotherapy protocols tested, OIT for peanut allergy has elicited a strong desensitisation effect in several trials (14). Peanut allergen is orally administered either in natural or processed form in gradually increasing doses, with the goal of establishing tolerance to ingestion. This concept of OIT was first used by Schofield in 1908 and reclaimed application in the 1990’s with the observed increasing prevalence of food allergies (15). OIT can induce desensitisation of an allergic individual to a specific allergen, thereby providing potential protection against accidental ingestion and improving quality of life. The underlying immunological mechanisms of OIT are the subject of current research and have been associated with decreased basophil reactivity (16), increased serum IgG₄ and IgA and initial increase followed by decrease in serum food-specific IgE...
(17). Allergen-specific memory B cells expanding during OIT point to a potential role of these cells in tolerance acquisition (18).

Although the majority of OIT-treated individuals pass the exit food challenges with an ability to tolerate increased amounts of peanut protein compared to baseline, the regimen of increasing allergen doses and performing food challenges is time-consuming, requires close supervision by medical personnel and carries a risk of inducing a severe allergic reaction including anaphylaxis (19). To maintain a state of desensitisation, ongoing daily intake of peanut allergen is required, because it is unknown whether clinical protection will be sustained indefinitely.

In this review, we discuss the recently approved OIT treatment PALFORZIA and emerging approaches applied in clinical trials for peanut allergy that are aimed at improving tolerability and treatment adherence. Alternative non-IgE reactive formulations currently being investigated in clinical trials for other routes of administration are also considered for improved strategies for peanut allergy OIT.

**Oral immunotherapy advances for peanut allergy**

**PALFORZIA: the first approved oral immunotherapy for peanut allergy**

The international phase 3, randomised, double-blind placebo-controlled study PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitisation in children and adults) tested efficacy and safety of AR101 (Aimmune Therapeutics, Inc. US), the investigational oral biologic drug containing peanut allergen powder (from defatted peanut flour), in peanut-allergic individuals aged 4-55 years (Table 1) (20). This trial has recently led to registration of the OIT product PALFORZIA® in the US and Europe (21, 22). The primary analysis of the PALISADE trial in 496 patients aged 4–17 years indicated that 67.2% of AR101-treated patients tolerated a single highest dose of at least 600 mg of peanut protein, whereas this dose was tolerated by only 4.0% of placebo-treated
patients. During the trial, systemic allergic reactions and severe adverse events were observed in 14.2% and 6% of the active group, respectively, and 3.2% and 2% of the placebo group. These adverse events led to withdrawal from the study of 11.6% of the active group and 2.4% of the placebo group. Excluding systemic allergic reactions treated during the food challenges, epinephrine was administered in 14% of the active group and 6.5% of the placebo group (20).

The treatment is now available in the US and in Europe through a restricted program called the PALFORZIA risk evaluation and mitigation strategy (REMS) program. Healthcare providers and facilities require certification with this program prior to initiation of PALFORZIA treatment. Patients undergoing OIT with PALFORZIA do achieve an increased tolerance of peanut protein ingestion, but the protocol carries certain challenges (Figure 1). The treatment period of approximately 6-7 months requires the patients and their families to regularly adhere to periodical medical supervision and high costs. The risk for allergic reactions persists, particularly when patients are unsupervised at home, and anxiety for these adverse events predicts a drop-out rate of ~20%, similar to that observed in the PALISADE trial (20).

Improving the OIT protocol: timing, dosing and allergen presentation

The risk of adverse events with peanut OIT has triggered several clinical studies with amended protocols of OIT procedures to improve tolerability of treatment and decrease drop-out rates and anxiety levels in patients. The first approach to improve tolerability of OIT in sensitised individuals is to slow down up-dosing and maintenance phases, escalate more gradually and to use lower amounts of allergen. A double-blind, placebo-controlled clinical trial conducted by Blumchen et al. tested a peanut OIT protocol with an extended up-dosing phase of up to 14 months and a maintenance phase of 8 weeks (23). The final open food challenge displayed desensitisation to 300
mg of peanut protein with improvement on the safety profile (Table 1). No epinephrine-requiring adverse events were encountered with fewer participant drop-outs (6.7%) recorded.

A second approach is to reduce immunoreactivity of peanuts through thermal and chemical treatments. Enzymatic hydrolysis through heated water treatment of peanuts was identified as most effective in diminishing the allergenic potential of peanuts (24). A hypoallergenic product generated from boiled peanuts was used in the BOPI-1 study (Boiled peanut oral immunotherapy for peanut allergy: a pilot study, NCT02149719) (Table 1). In this phase 2b/3 trial for 12 months of treatment on 47 children aged 8-16 years, participants underwent a repeat double-blind, placebo-controlled food challenge (DBPCFC) and achieved the primary outcome of desensitisation to >1.44 g peanut protein (p<0.0001).

An open trial sponsored by Imperial College London is currently recruiting for the follow-up study BOPI-2 (Table 1) (NCT03937726) to demonstrate effectiveness of boiled peanut as compared to regular peanut flour for OIT. The study aims to compare the rate of adverse events between the two interventions, will assess the immunological mechanisms involved and develop clinically useful predictors for identifying individuals likely to achieve successful desensitisation.

Australian investigators also aim to increase safety of desensitisation and decrease capacity to cause adverse events using hypoallergenic peanut preparations in their phase 2 trial ACTRN12617000803392 (Table 1) (25). A total of 66 peanut-allergic children are being treated with the HYPES (Hypoallergenic peanuts eaten safely) protocol with 3 phases of treatment: very low allergenicity (12-hour heat-treated) peanuts followed by 2-hour heat-treated peanuts and finally roasted peanuts over a combined total of 52 weeks. The results are expected by the end of 2021 and will indicate if appropriate processing techniques can diminish peanut allergenicity in a clinically relevant setting.
Dutch researchers have shown a lower IgE-binding and capacity to induce allergic symptoms in peanut-allergic patients using chemically modified peanut extract (reduction and alkylation) as compared to unmodified peanut extract (26). A clinical trial led by Danish researcher Bindslev-Jensen administered chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) subcutaneously in a phase 1, single-centre clinical trial NCT02163018 (Table 1) and reported safety and tolerability with immunological changes in peanut-allergic patients (27). Further trials using modified allergen extracts and formulations for OIT will determine if tolerability of administration can be improved.

Biologics and dietary supplements as adjuvants to improve OIT efficacy and minimise adverse events

Biologics, including drugs and immunomodulating agents or dietary supplements such as prebiotics or probiotics can help to stimulate, enhance or modulate the immune response and therefore help to manage symptoms when given in concert with OIT.

Omalizumab

The biological agent most utilised in the field of food allergy is Omalizumab (brand name Xolair, Genentech, Inc./Novartis Pharmaceuticals, Basel, Switzerland), an anti-IgE monoclonal antibody (mAb) currently approved for treatment of severe asthma and chronic spontaneous urticaria (28). Omalizumab selectively binds to soluble IgE, thereby downregulating the expression of FcεRI on mast cells and basophils (28). Omalizumab has been shown to significantly raise the tolerance threshold to food allergens and can be used as an adjunct to OIT, enabling rapid and safe escalation of food doses (29). A Swedish study NCT02402231 (Table 1) showed that Omalizumab was an effective adjunctive therapy for initiation and rapid up-dosing of OIT for peanut allergy with very
rare incidences of moderate systemic allergic reactions (30). However, upon lowering Omalizumab intake, the adverse events from peanut OIT became more frequent (30).

Following this Swedish initiative, several studies are now trialling the utility of Omalizumab as adjunct therapy for OIT. This includes the Australian phase 4 trial OPAL (ACTRN12620001203943) (Table 1), a planned single-arm study to evaluate improved safety and patient acceptability over the full course of peanut OIT. OIT for multiple food allergies, including peanut, using Omalizumab induction treatment, is currently being tested in a phase 3 multicentre placebo-controlled clinical trial (NCT03881696) (Table 1) under breakthrough designation by the US Food and Drug Administration (FDA). The designation is based on data from several clinical trials, which assessed Omalizumab’s efficacy and safety in combination with OIT for food allergens, including peanut, milk, and egg (31).

These and emerging trials will demonstrate if there is a clear benefit of Omalizumab-enabled accelerated OIT (OEOAOIT) over standard OIT. A clinical advantage of Omalizumab would be a significantly decreased length of the up-dosing phase, which is the most labour-intensive and resource-consuming part of the treatment. In these trials, the dose of Omalizumab used was determined from the asthma dosage chart based on patient weight and total IgE (29). The optimal dose to be used as an adjunct for OIT remains to be determined.

**Dupilumab**

Dupilumab (brand name Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc. New York, US) is the first approved biologic by the FDA and European Medicines Agency for the treatment of atopic dermatitis (AD) with current investigations in patients with Th2-mediated bronchial asthma (32). This therapeutic mAb is directed against the IL-4 receptor α chain (IL4Rα) and inhibits ligand binding (33). As the IL4Rα is part of both the IL-4 and IL-13 receptors, Dupilumab interferes with both the IL-4 and
IL-13 signals. Consequently, this may decrease mast cell recruitment to the mucosa (34), thereby downregulating allergic responses and the risk of adverse events from OIT.

Regeneron Pharmaceuticals has an active trial ‘Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of Dupilumab as adjunct to AR101’ (Table 1). This phase 2, multicentre, placebo-controlled study aims to assess whether Dupilumab improves desensitisation at the completion of the up-dosing phase of AR101 OIT with a DBPCFC at week 16 of the protocol (NCT03682770). Another objective of this trial is to evaluate safety and tolerability of Dupilumab as an adjunct to AR101 and to assess the immunological changes in peanut-specific IgE/IgG4 ratio.

**Abatacept**

Abatacept (brand name Orencia, Bristol-Myers Squibb, New York, US) is a fusion protein of the extracellular domain of the human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) linked to the Fc domain of human immunoglobulin 1 (IgG1). Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), blocking interaction with CD28 on T cells and therefore T cell activation. Thus far, Abatacept treatment has been shown to be effective in patients with various autoinflammatory diseases (35) and belongs to a new class of medicines called biological disease modifying anti-rheumatic drugs (DMARDs). An incidence rate of infections over long-term use (> 6 months) has been reported (36), which may limit the timeframe for administration as an adjunct for OIT protocols. Currently, Abatacept is being tested as an adjuvant to OIT for peanut allergy (37); results of this trial may identify potential adverse effects such as increased infections. The Canadian phase 2a, multi-centre, randomised and double-blind placebo-controlled trial ATARI (NCT04872218) (Table 1) aims to compare 24 weeks of Abatacept versus placebo as adjuvant to peanut OIT with anticipated completion in 2023. The primary outcome is the relative change in peanut-specific/total IgE from baseline to week 24. Secondary outcomes are
relative change in peanut-specific IgG4/IgE ratio at week 24 and sustained tolerance assessed between week 36 and 48, in addition to the highest tolerated dose of an oral food challenge at week 36.

**Pre- and Probiotics**

The use of probiotics as microbial adjunct therapy for OIT can enhance tolerability and decrease gastrointestinal adverse events. A double-blind placebo-controlled randomised study evaluated the effect of *Lactobacillus rhamnosus* CGMCC1.3724 in combination with peanut OIT in 62 children aged 1-10 years on the induction of sustained clinical unresponsiveness 2 to 5 weeks after discontinuation of treatment ([Table 1](#)) (38). The probiotic *Lactobacillus rhamnosus* CGMCC1.3724 (NCC4007) has been reported to induce Treg cells, antigen-specific IgA and T helper (Th)1 cytokine responses (39, 40), and administration of this probiotic with peanut OIT (PPOIT) could support redirection of the peanut-specific allergic response towards tolerance. Clinical unresponsiveness two weeks post-treatment regimen was achieved in 82.1% receiving PPOIT and 3.6% receiving placebo (P<0.001), associated with decreased peanut skin prick test responses, peanut-specific IgE levels and increased peanut-specific IgG4 levels (all P<0.001) (38). The study failed to include a probiotic only or OIT only group limiting the ability to fully ascertain the contribution of either of the two constituents of PPOIT.

The long-term follow-up study PPOIT2 published in 2017 ([Table 1](#)) aimed to examine whether the previously reported clinical and immunological benefits of PPOIT were maintained 4 years after treatment and found that sustained unresponsiveness was maintained without the need to follow a regular pre-specified ingestion schedule (41). These results provide a compelling argument that PPOIT induced clinical and immunological tolerance. The investigators intend to analyse microbial composition of stool samples in future studies to examine the effects of PPOIT on the gut.
microbiome (41). The phase 3, multi-centre, 3 arm randomised controlled trial PPOIT-003 (ACTRN12616000322437) (Table 1) was conducted in 3 children’s hospitals in Australia with 200 participants aged between 1 and 10 years of age to evaluate the effectiveness of PPOIT in inducing sustained unresponsiveness compared with peanut OIT alone and with placebo, with complete data analysis anticipated by the end of 2021.

Another Australian interventional study (ACTRN12617000914369) (Table 1) will assess clinical tolerance and sustained unresponsiveness after administration of a modified dietary fiber (butyrylated high amylose maize starch) in conjunction with a daily dose of roasted peanut powder in peanut-allergic children. This prebiotic adjunct strategy aims to enhance beneficial gut bacteria and increase the levels of the short chain fatty acid butyrate, which may promote a non-allergic environment (42, 43).

**Alternative formulations for OIT for peanut allergy**

In addition to whole peanut protein preparations and adjunctive therapeutics, alternative allergen forms for immunotherapy are being researched and trialled to overcome the associated adverse events of exposing the gastrointestinal tract to whole allergenic protein. DNA vaccines and peptide therapeutics are under investigation for other routes of administration and could be considered for OIT. Hypoallergenic preparations also offer an alternative. These interventions potentially could decrease treatment duration, the need for strict medical supervision and may lead to higher patient adherence.
**DNA vaccines**

A novel immunotherapeutic approach utilises intradermal administration of plasmid DNA encoding peanut allergens and is currently being tested for safety, tolerability and immune response in a phase 1 trial (NCT03755713) (Table 1) in 20 patients aged 12 to 17 years. The ARA-LAMP-vax (Immunomic Therapeutics Inc., Pennsylvania, US) comprises one DNA plasmid encoding the major peanut allergens Ara h 1, Ara h 2 and Ara h 3, encoded as fusion proteins with lysosomal associated membrane protein (LAMP) (44). Immunomic Therapeutics hypothesise that this plasmid DNA vaccination is a strategy to activate natural killer (NK) cells that produce Interferon gamma (IFNγ) (45), influencing skewing of Th cell responses. The LAMP technology diverts the synthesised Ara h protein products of the vaccine directly to the lysosome in the dendritic cells, making them readily available to form antigen-MHC-II complexes. Once on the cell surface, these MHC-II complexes can directly interact with Th cells and in the presence of IFNγ, lead to the production of antibodies and Th1 cytokines (45, 46). Trial completion is anticipated by the end of 2021, and results will inform treatment safety and whether the immune response could be redirected from a Th2/ IgE allergen-specific response to a Th1/ IgG response.

Vaccination with plasmid DNA will need further proof against apprehensions about safety of this vaccine type, categorised as gene therapy. Issues have been raised due to the hypothetical risk of integration of the vaccine itself into the genome or long-term persistence of the administered plasmid DNA that could lead to triggering production of anti-DNA antibodies (47). These aspects will require further consideration. A potential alternative methodology would be an mRNA-based vaccine, without the capacity to integrate into the host genome, as has been extremely successful in vaccines against SARS-CoV-2 (48, 49).
**Modified peanut allergen preparations and other adjuvants**

Other vaccination approaches are currently undergoing pre-clinical testing in animal studies. A study performed by Storni et al. used peanut-sensitised mice to demonstrate a protective effect of vaccination with extracts of roasted peanut or the single allergens Ara h 1 or Ara h 2 coupled to immunologically optimised Cucumber Mosaic Virus–derived virus-like particles (CuMVtt) (50). Modified hypoallergenic preparations are proving advantageous for other allergies and could also be considered for safe treatment of peanut allergy (51). In particular, potential induction of eosinophilic oesophagitis by OIT could be averted by using hypoallergenic preparations (52).

The alteration of allergenic protein structure and function influences immunoreactivity and allergenicity (24). Amongst these approaches, the most advantageous for diminishing the allergenic potential of peanut is enzymatic hydrolysis (53). Further investigations have shown reduced allergenicity using a combination of enzymatic hydrolysis followed by, or in conjunction with, roasting (54), high pressure and heat (55) or ultrasound with enzymatic treatment (56), collectively called Hurdle technology.

**Peptide immunotherapy**

An alternative approach to prevent IgE-mediated adverse events is to utilise T-cell reactive peptide fragments of the allergen that are not recognised by antibodies (57). Australian researchers have designed a peanut peptide product designed to induce tolerance to peanuts and decrease the risk of severe allergic reactions upon accidental exposure (58, 59). Biotechnology company Aravax Pty Ltd (Melbourne, Australia) conducted a double-blind placebo-controlled Phase 1 trial (ACTRN12617000692336) (Table 1) in peanut-allergic adults to test PVX108, a mixture of synthetic peptides that represent immunodominant T-cell epitopes of Ara h 1 and Ara h 2 (58, 59). The Phase 1 study comprised two phases, the first of
which assessed single, ascending doses (0.05 nmol – 150 nmol) of PVX108 and enrolled eight patient cohorts, randomised to receive PVX108 or placebo by intradermal injection with staggered successive cohort dosing such that the eighth cohort received the highest dose. In the second phase, 18 additional subjects were randomised to receive six injections of 150 nmol PVX108 over a 16-week period. The Phase 1 study demonstrated that PVX108 had a highly favourable safety profile, even for patients with severe peanut allergies. No treatment-related reactions deemed to be of clinical concern by the Safety Review Committee and no “allergic” adverse events were noted. Additionally, there was a demonstrated lack of \textit{in vitro} basophil reactivity to PVX108, providing further support for an improved safety profile of PVX108 over whole allergen immunotherapies (60).

\textbf{Conclusions}

OIT enables administration of much higher doses of allergen with greater safety than other routes of administration of AIT. The recently approved peanut OIT product PALFORZIA represents a promising treatment option for peanut-allergic patients to increase the threshold of clinical tolerance for protection from accidental ingestion and possibly achieving sustained unresponsiveness. Clinical data collection of healthcare providers in the REMS program will help ongoing research in assessing the effectiveness of PALFORZIA in the real-world setting and guide future clinical trial design for OIT.

This and other new strategies to enhance the safety and efficacy of immunotherapy for peanut allergy are currently under clinical exploration. Promising trends amongst different protocols and methods to improve OIT success with decreased adverse events are to alter OIT protocols regarding timing and dosing: a lower allergen delivery dose and a slow, delayed escalation rate in OIT treatment seem approachable in the near future.
Adjunctive therapy with biologics in parallel to OIT protocols may help to mitigate risk and improve tolerability, especially in highly allergic individuals. Many trials using the biologic Omalizumab as adjunctive treatment in OIT have shown a raised threshold tolerance dose of OIT treatment, thereby reducing the risk of severe adverse reactions. Other biologics such as Abatacept are not optimal for extended use, which limits their application in OIT protocols. Dietary supplements such as probiotics have been shown to improve treatment tolerability with decreased adverse effects over longer periods of time, presenting a cost-effective adjunct treatment with OIT.

Alternative formulations that circumvent exposure of the gastrointestinal tract to IgE-reactive, whole allergenic proteins, such as peptides, DNA vaccines and other hypoallergenic preparations, could present a safer, more cost-effective approach for OIT for peanut allergic individuals.

More studies are needed to fully elucidate the best protocol to achieve sustained unresponsiveness. Most current clinical trials include objective laboratory biomarker analysis in patients undergoing OIT protocols (8). The rapid developments in identifying new biomarkers for early prediction of treatment success may facilitate understanding of underlying immunological mechanisms and possibly stratify those patients at higher risk for adverse reactions (61).
Funding

Supported by an NHMRC Senior Research Fellowship (GNT1117687; MCvZ), an NHMRC Ideas grant (GNT2000773; MCvZ, ROH).

Author contributions

SR, MCvZ, wrote the manuscript. JMR and ROH contributed extensive discussions, and edited draft versions of the manuscript.

Conflict of interest

MCvZ and ROH are inventors on a patent application related to this work. ROH and JMR are inventors and cofounders of Aravax Pty. Ltd. SR declares no conflict of interest.

Data availability

There are no novel data generated associated with this review article.

Acknowledgements

The Editor-in-Chief, Tim Elliott, would like to thank Adriana Bonomo and Ana Maria Faria for their contribution to the peer review of this article.
References

1. Abrams EM, Chan ES, Sicherer S; Peanut Allergy: New Advances and Ongoing Controversies. *Pediatrics* 2020;145(5). doi: 10.1542/peds.2019-2102.

2. Krogulska A, Wood RA; Peanut allergy diagnosis: Moving from basic to more elegant testing. *Pediatr Allergy Immunol* 2020;31(4):346-357. doi: 10.1111/pai.13215.

3. Mueller GA, Maleki SJ, Pedersen LC; The molecular basis of peanut allergy. *Curr Allergy Asthma Rep* 2014;14(5):429. doi: 10.1007/s11882-014-0429-5.

4. Kukkonen AK, Pelkonen AS, Makinen-Kiljunen S, et al.; Ara h 2 and Ara 6 are the best predictors of severe peanut allergy: a double-blind placebo-controlled study. *Allergy* 2015;70(10):1239-45. doi: 10.1111/all.12671.

5. Palladino C, Breiteneder H; Peanut allergens. *Mol Immunol* 2018;100:58-70. doi: 10.1016/j.molimm.2018.04.005.

6. Cabanillas B, Jappe U, Novak N; Allergy to Peanut, Soybean, and Other Legumes: Recent Advances in Allergen Characterization, Stability to Processing and IgE Cross-Reactivity. *Mol Nutr Food Res* 2018;62(1). doi: 10.1002/mnfr.201700446.

7. Dorofeeva Y, Shilovskiy I, Tulaeva I, et al.; Past, present, and future of allergen immunotherapy vaccines. *Allergy* 2021;76(1):131-149. doi: 10.1111/all.14300.

8. van Zelm MC, McKenzie CI, Varese N, et al.; Recent developments and highlights in immune monitoring of allergen immunotherapy. *Allergy* 2019;74(12):2342-2354. doi: 10.1111/all.14078.

9. Patrawala M, Shih J, Lee G, et al.; Peanut Oral Immunotherapy: a Current Perspective. *Curr Allergy Asthma Rep* 2020;20(5):14. doi: 10.1007/s11882-020-00908-6.

10. Worm M, Francuzik W, Dölle S, et al.; Current developments in the treatment of peanut allergy. *Allergo Journal International* 2021;30(2):56-63. doi: 10.1007/s40629-021-00164-8.

11. Jones SM, Sicherer SH, Burks AW, et al.; Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults. *J Allergy Clin Immunol* 2017;139(4):1242-1252 e9. doi: 10.1016/j.jaci.2016.08.017.

12. Jones SM, Agbotoumou WK, Fleischer DM, et al.; Safety of epicutaneous immunotherapy for the treatment of peanut allergy: A phase 1 study using the Viaskin patch. *J Allergy Clin Immunol* 2016;137(4):1258-1261 e10. doi: 10.1016/j.jaci.2016.01.008.

13. Kim EH, Yang L, Ye P, et al.; Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. *J Allergy Clin Immunol* 2019;144(5):1320-1326 e1. doi: 10.1016/j.jaci.2019.07.030.

14. Kim EH, Patel C, Burks AW; Immunotherapy approaches for peanut allergy. *Expert Rev Clin Immunol* 2020;16(2):167-174. doi: 10.1080/1744666X.2019.1708192.

15. Ring J, Gutermuth J; 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). *Allergy* 2011;66(6):713-24. doi: 10.1111/j.1398-9995.2010.02541.x.
16. Thyagarajan A, Jones SM, Calatroni A, et al.; Evidence of pathway-specific basophil anergy induced by peanut oral immunotherapy in peanut-allergic children. Clin Exp Allergy 2012;42(8):1197-205. doi: 10.1111/j.1365-2222.2012.04028.x.

17. Vickery BP, Lin J, Kulis M, et al.; Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol 2013;131(1):128-34 e1-3. doi: 10.1016/j.jaci.2012.10.048.

18. Patil SU, Ogguniyyi AO, Calatroni A, et al.; Peanut oral immunotherapy transiently expands circulating Ara h 2-specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol 2015;136(1):125-134 e12. doi: 10.1016/j.jaci.2015.03.026.

19. Chu DK, Wood RA, French S, et al.; Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet 2019;393(10187):2222-2232. doi: 10.1016/S0140-6736(19)30420-9.

20. Investigators PGoC, Vickery BP, Vereda A, et al.; AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med 2018;379(21):1991-2001. doi: 10.1056/NEJMoa1812856.

21. Therapeutics A. FDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut Allergy. https://ir.aimimmune.com/news-releases/news-release-details/fda-approves-aimmune-palforziatm-first-treatment-peanut-allergy (Date Accessed 2020 Accessed, date last accessed)

22. Therapeutics A. European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU. https://ir.aimimmune.com/news-releases/news-release-details/european-commission-approves-aimmune-palforziar-first-ever (Date Accessed 2020 Accessed, date last accessed)

23. Blumchen K, Trendelenburg V, Ahrens F, et al.; Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy. J Allergy Clin Immunol Pract 2019;7(2):479-491 e10. doi: 10.1016/j.jaip.2018.10.048.

24. Shah F, Shi A, Ashley J, et al.; Peanut Allergy: Characteristics and Approaches for Mitigation. Compr Rev Food Sci Food Saf 2019;18(5):1361-1387. doi: 10.1111/1541-4337.12472.

25. Tao B, Morris S, Grzeskowiak L, et al.; Sequential hypoallergenic boiled peanut and roasted peanut oral immunotherapy. Clin Exp Allergy 2017;47(11):1501-1504. doi: 10.1111/cea.13024.

26. van der Kleij HPM, Warmenhoven HJM, van Ree R, et al.; Chemically modified peanut extract shows increased safety while maintaining immunogenicity. Allergy 2019;74(5):986-995. doi: 10.1111/all.13687.

27. Bindslev-Jensen C dKP, van Twuijver E, Boot Boot D, El Galta R, Pahlow Mose A, Kring Tannert L, Opstelten DJ.; SCIT-treatment With a Chemically Modified, Aluminum Hydroxide Adsorbed Peanut Extract (HAL-MPE1) Was Generally Safe And Well Tolerated And Showed Immunological Changes In Peanut Allergic Patients. Journal of Allergy and Clinical Immunology 2017;139(2). doi: 10.1016/j.jaci.2016.12.623.

28. Pelaia G, Canonica GW, Matucci A, et al.; Targeted therapy in severe asthma today: focus on immunoglobulin E. Drug Des Devel Ther 2017;11:1979-1987. doi: 10.2147/DDDT.S130743.
29. Langlois A, Lavergne MH, Leroux H, et al.; Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. *Allergy Asthma Clin Immunol* 2020;16:25. doi: 10.1186/s13223-020-00419-z.

30. Brandstrom J, Vetander M, Sundqvist AC, et al.; Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. *Clin Exp Allergy* 2019;49(10):1328-1341. doi: 10.1111/cea.13469.

31. Sampson HA, Berin MC, Plaut M, et al.; The Consortium for Food Allergy Research (CoFAR): The first generation. *J Allergy Clin Immunol* 2019;143(2):486-493. doi: 10.1038/s41598-019-44253-9.

32. Rial MJ, Barroso B, Sastre J; Dupilumab for treatment of food allergy. *J Allergy Clin Immunol Pract* 2019;7(2):673-674. doi: 10.1016/j.jaip.2018.07.027.

33. Kim JE, Jung K, Kim JA, et al.; Engineering of anti-human interleukin-4 receptor alpha antibodies with potent antagonistic activity. *Sci Rep* 2019;9(1):7772. doi: 10.1038/s41598-019-44253-9.

34. Kanagaratham C, El Ansari YS, Lewis OL, et al.; IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy. *Front Immunol* 2020;11:603050. doi: 10.3389/fimmu.2020.603050.

35. Bonelli M, Scheinecker C; How does abatacept really work in rheumatoid arthritis? *Curr Opin Rheumatol* 2018,30(3):295-300. doi: 10.1097/BOR.0000000000000491.

36. Alten R, Kaine J, Keystone E, et al.; Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. *Arthritis Rheumatol* 2014;66(8):1987-97. doi: 10.1002/art.38687.

37. Abbasi M, Mousavi MJ, Jamali-Zehi S, et al.; Strategies toward rheumatoid arthritis therapy; the old and the new. *J Cell Physiol* 2019;234(7):10018-10031. doi: 10.1002/jcp.27860.

38. Tang ML, Ponsonby AL, Orsini F, et al.; Administration of a probiotic with peanut oral immunotherapy: A randomized trial. *J Allergy Clin Immunol* 2015;135(3):737-44.e8. doi: 10.1016/j.jaci.2014.11.034.

39. Pohjavuori E, Viljanen M, Korpela R, et al.; Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. *J Allergy Clin Immunol* 2004;114(1):131-6. doi: 10.1016/j.jaci.2004.03.036.

40. Miettinen M, Matikainen S, Vuopio-Varkila J, et al.; Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells. *Infect Immun* 1998;66(12):6058-62. doi: 10.1128/IAI.66.12.6058-6062.1998.

41. Hsiao KC, Ponsonby AL, Axelrad C, et al.; Long-term clinical and immunological effects of probiotic and peanut oral immunotherapy after treatment cessation: 4-year follow-up of a randomised, double-blind, placebo-controlled trial. *Lancet Child Adolesc Health* 2017;1(2):97-105. doi: 10.1016/S2352-4642(17)30041-X.

42. Lynch SV; Gut Microbiota and Allergic Disease. New Insights. *Ann Am Thorac Soc* 2016;13 Suppl 1:S51-4. doi: 10.1513/AnnalsATS.201507-451MG.
Gill PA, van Zelm MC, Muir JG, et al.; Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. *Aliment Pharmacol Ther* 2018;48(1):15-34. doi: 10.1111/apt.14689.

Therapeutics I. *Immunomic Therapeutics and Astellas Pharma announce exclusive licensing agreement for LAMP-Vax platform to prevent and treat allergies. https://www.immunomicx.com/immunomic-therapeutics-and-astellas-pharma-announce-exclusive-licensing-agreement-for-lamp-vax-platform-to-prevent-and-treat-allergies/* (Date Accessed 2015 Accessed, date last accessed)

Rettman P, Blunt MD, Fulton RJ, et al.; Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors. *J Immunother Cancer* 2021;9(5). doi: 10.1136/jitc-2020-001912.

Scheiblhofer S, Thalhamer J, Weiss R; DNA and mRNA vaccination against allergies. *Pediatr Allergy Immunol* 2018;29(7):679-688. doi: 10.1111/pai.12964.

Fathizadeh H, Afshar S, Masoudi MR, et al.; SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. *Int J Biol Macromol* 2021;188:740-750. doi: 10.1016/j.ijbiomac.2021.08.076.

Baden LR, El Sahly HM, Essink B, et al.; Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384(5):403-416. doi: 10.1056/NEJMoa2035389.

Nilsson C, Scurlock AM, Dellon ES, et al.; Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy. *J Allergy Clin Immunol Prac* 2021. doi: 10.1016/j.jaip.2021.07.048.

Yu J, Ahmedna M, Goktepe I, et al.; Enzymatic treatment of peanut kernels to reduce allergen levels. *Food Chem* 2011;127(3):1014-22. doi: 10.1016/j.foodchem.2011.01.074.

Mikiashvili N, Yu J; Changes in immunoreactivity of allergen-reduced peanuts due to post-enzyme treatment roasting. *Food Chem* 2018;256:188-194. doi: 10.1016/j.foodchem.2018.02.119.

Hu CQ, Chen HB, Gao JY, et al.; High-pressure microfluidisation-induced changes in the antigenicity and conformation of allergen Ara h 2 purified from Chinese peanut. *J Sci Food Agric* 2011;91(7):1304-9. doi: 10.1002/jsfa.4318.

Li H, Yu J, Ahmedna M, et al.; Reduction of major peanut allergens Ara h 1 and Ara h 2, in roasted peanuts by ultrasound assisted enzymatic treatment. *Food Chem* 2013;141(2):762-8. doi: 10.1016/j.foodchem.2013.03.049.

O’Hehir RE, Prickett SR, Rolland JM; T Cell Epitope Peptide Therapy for Allergic Diseases. *Curr Allergy Asthma Rep* 2016;16(2):14. doi: 10.1007/s11882-015-0587-0.
58. Prickett SR, Voskamp AL, Phan T, et al.; Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic. *Clin Exp Allergy* 2013;43(6):684-97. doi: 10.1111/cea.12113.

59. Prickett SR, Voskamp AL, Dacumos-Hill A, et al.; Ara h 2 peptides containing dominant CD4+ T-cell epitopes: candidates for a peanut allergy therapeutic. *J Allergy Clin Immunol* 2011;127(3):608-15 e1-5. doi: 10.1016/j.jaci.2010.09.027.

60. Prickett S, Hickey P, Bingham J, et al.; Safety and Tolerability of a Novel Peptide-Based Immunotherapy for Peanut Allergy. *Journal of Allergy and Clinical Immunology* 2019;143(2). doi: https://doi.org/10.1016/j.jaci.2018.12.975.

61. van Zelm MC, McKenzie CI, Varese N, et al.; Advances in allergen-specific immune cell measurements for improved detection of allergic sensitization and immunotherapy responses. *Allergy* 2021. doi: 10.1111/all.15036.
Table 1. Clinical studies for peanut immunotherapy

| Category | Trial identifier | Phase | Name of trial/study | References |
|----------|------------------|-------|---------------------|------------|
| EPIT     | NCT01170286      | Phase 1 | Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy | (12) |
| SLIT     | NCT01373242      | Phase 1 | Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance (SLIT-TLC) | (13) |
|          |                  | Phase 2 |                     |            |
| OIT      | NCT02635776      | Phase 3 | Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) | (20) |
| DRKS00004553 | N/A             |       | A randomized, double-blind, placebo-controlled study of oral immunotherapy in peanut-allergic children | (23) |
| NCT02149719 | Phase 2b/3     |       | Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study (BOPI-1) | |
| NCT03937726 | N/A             |       | Boiled peanut immunotherapy for the treatment of peanut allergy (BOPI-2) | |
| ACTRN12617000803392 | Phase 2 |       | HYPES: Peanut allergy desensitisation using sequential hypoallergenic and roasted peanuts | (25) |
| NCT02163018 | Phase 1         |       | A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients | |
| Treatment                        | NCT | Phase | Description                                                                 |
|---------------------------------|-----|-------|-----------------------------------------------------------------------------|
| Omalizumab + OIT                | NCT02402231 | Phase 2 | Treatment of severe peanut allergy with Xolair (Omalizumab) and oral immunotherapy (FASTX) |
| ACTRN12620001203943             |     | Phase 4 | OPAL: Combining peanut oral immunotherapy and Omalizumab in adults with peanut allergy |
| NCT03881696                    |     | Phase 3 | Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic participants (OUtMATCH) |
| Dupilumab + OIT                | NCT03682770 | Phase 2 | Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of Dupilumab as adjunct to AR101 (peanut oral immunotherapy) |
| Abatacept + OIT                | NCT04872218 | Phase 2 | Adjuvant Treatment with Abatacept to promote remission during peanut oral immunotherapy (ATARI) |
| Probiotics + OIT               | ACTRN12608000594325 | N/A | Study of effectiveness of probiotics and peanut oral immunotherapy (OIT) in inducing desensitisation or tolerance in children with peanut allergy |
| ACTRN12615001275550            |     | N/A | Safety and efficacy of Probiotic and Peanut Oral Immunotherapy (PPOIT) for the induction of sustained unresponsiveness in children with peanut allergy. |
| Study Type | ACTRN/Identifier | Phase | Description |
|------------|------------------|-------|-------------|
| Prebiotics + OIT | ACTRN12617000914369 | N/A | Oral peanut immunotherapy with a modified dietary starch adjuvant for treatment of peanut allergy in children aged 10-16 years |
| DNA vaccine | NCT03755713 | Phase 1 | A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine |
| Peptide immunotherapy | ACTRN12617000692336 | Phase 1 | Phase I trial to assess the safety and tolerability of PVX108 in peanut-allergic adults |
Figure 1. OIT strategies for specific immunotherapy for peanut allergy.

a) Typical OIT protocol. Most trials end with a DBPCFC, some with follow-up testing for sustained unresponsiveness. b) OIT protocols with adjunct biologicals or dietary supplements. Monoclonal antibodies (e.g. Omalizumab, Dupilumab or Abatacept) or prebiotics / probiotics are introduced either before or at the start of OIT, depending on the protocol. c) Alternative non-IgE reactive formulations for OIT.
